untitled design

Anvisa approves new HIV treatment

Anvisa announced this Monday (29) that it has approved a new drug for the treatment of HIV. It combines two substances – lamivudine and dolutegravir sodium – in a single tablet.

According to the agency, the possibility of single doses action simplifies the treatment and adherence of patients to treatment.

According to the leaflet approved by Anvisa, the new drug reduces the amount of HIV in the body, keeping it at a low level. In addition, it promotes an increase in the count of CD4 cells, a type of white blood cell that plays an important role in maintaining a healthy immune (defence) system, helping to fight infections.

The drug may be indicated as a complete regimen for the treatment of infection by the human immunodeficiency virus type 1 (HIV-1) in adults and adolescents over 12 years old weighing at least 40 kg, with no history of previous antiretroviral treatment or in substitution for current antiretroviral regimen in virologically suppressed people.

Reference: CNN Brasil

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular